Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Fairooz Kabbinavar, MD
Chief Medical Officer
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Mcgill University
Montreal, Quebec, Canada
- St. James'S Hospital
Dublin, Ireland
- St. Vincent'S University Hospital
Dublin, Ireland
- Ucla Medical Center
Los Angeles, California, United States
- Wilshire Oncology Medical Group, Inc.
Pomona, California, United States
- Cancer Institute of Florida, P.A.
Orlando, Florida, United States
- Northwest Georgia Oncology Centers, P.C.
Marietta, Georgia, United States
- South Texas Oncology and Hematology, P.A.
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2005
- Primary completion
- 30 Jun 2012
- Completion
- —
- Last update posted
- 12 Oct 2015
- Registered enrollment
- 6
- Registry id
- NCT00203372
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.